Until this kind of immune therapy is sold on the market, it will take some more time. The therapy is now in late stage development after more than a decade of work up till now. A large, 240-patient clinical trial is well under way in the US, and is planned to include 90 patients in Germany next spring. The results from two prior Phase I/II clinical trials in the US are promising: the median time until patients have recurrence of their tumor is only 6.9 months with standard of care (surgery plus radiation and chemotherapy) but was 2 years in patients treated with DCVax®; median survival time is only 14.6 months with standard of care but was 3 years in patients treated with DCVax®. Moreover, none of the patients treated with DCVax® experienced any toxic side effects. If the results in the large clinical trial now under way in the US (and planned to include Germany next spring) are similar to these prior trial results, the American company Northwest Biotherapeutics plans to seek accelerated approval in order to make the treatment widely available to patients as soon as possible.

"NW Bio's DCVax technology is one of the most exciting technologies I have seen in my career," commented Dr. Rosskamp, "and NW Bio has made impressive progress in their lead program for brain cancer in both the US and Europe, and in building a deep pipeline of additional applications and product lines. I am very pleased to join NW Bio and help with the ongoing clinical development, and the registration and commercialization of their DCVax products."

insider schreef:ik zat godverdomme in de file toen het ineens $20 stond : is dat nu niet om uw bloot ... van te laten kijken ??????????????